Literature DB >> 22296798

[Analysis of the rational use of anti-hypertensives in the Murcia (Spain) region].

Juan C Ruiz1, María A Ariza, Belén Aguilera, Mariano Leal, Ramón Gómez, José Abellán.   

Abstract

OBJECTIVE: The objective of this study was to determine the pattern of use of antihypertensive drugs in the Murcia Region, comparing the results with the national data, and detecting problems in order to make improvements, or establish hypotheses and to plan new studies.
DESIGN: Pharmacoepidemiological study (from 2004 to 2008) in accordance with the recommendations from World Heath Organization.
SETTING: : Murcia Region. PARTICIPANTS: Annual census of each year. MAIN MEASUREMENTS: The use of antihypertensive drugs was measured by the daily doses per 1000 inhabitans-day (DHD).
RESULTS: The use of antihypertensive drugs has significantly increased from 196.6 DHD to 235.8 DHD. The antihypertensives more used at the end of 2008 were: angiotensin II receptor blockers-ARB- (38.6%) and angiotensin converting enzyme inhibitors-ACEI- (21.8%). There has been a tendency to change the use of rennin-angiotensin system blockers-RASB-, with an increase in ARB of 77.5% and and a decrease in ACEI 9.5%. The comparison with the national data shows qualitative and quantitative differences in the pattern of antihypertensive drugs used during the studied period.
CONCLUSIONS: The use of antihypertensive drugs in Murcia is less than in the rest of Spain. Therefore, this may be due to a problem of under treatment of this illness or other cardiovascular illnesses in the region. A greater use of ARB in Murcia and a lower use of ACEI was observed in Murcia. The differences found suggest that further studies are required to clarify their origins and causes, with the objective of achieving a more rational and efficient use of these drugs.
Copyright © 2010 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22296798      PMCID: PMC7025165          DOI: 10.1016/j.aprim.2011.04.006

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  23 in total

Review 1.  Treatment of hypertension in patients with type 2 diabetes: a review of the recent evidence.

Authors:  T A Chowdhury; S Kumar; A H Barnett; P M Dodson
Journal:  J Hum Hypertens       Date:  1999-12       Impact factor: 3.012

Review 2.  Angiotensin II-receptor blockers: clinical relevance and therapeutic role.

Authors:  J E Rodgers; J H Patterson
Journal:  Am J Health Syst Pharm       Date:  2001-04-15       Impact factor: 2.637

3.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

Authors:  B Pitt; P A Poole-Wilson; R Segal; F A Martinez; K Dickstein; A J Camm; M A Konstam; G Riegger; G H Klinger; J Neaton; D Sharma; B Thiyagarajan
Journal:  Lancet       Date:  2000-05-06       Impact factor: 79.321

4.  [Impact of a program of rational use of medicines on pharmaceutical prescription in a health area].

Authors:  J A Martínez Escudero; J E Baeza Berruti; J A Rubio-Manzanares Bermejo; M C Palacios López
Journal:  Aten Primaria       Date:  1996-12       Impact factor: 1.137

5.  Global burden of hypertension: analysis of worldwide data.

Authors:  Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He
Journal:  Lancet       Date:  2005 Jan 15-21       Impact factor: 79.321

6.  [Impact of various objectives related to the rational use of medication in a primary care area].

Authors:  X M Segade Buceta
Journal:  Aten Primaria       Date:  2000-03-15       Impact factor: 1.137

Review 7.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group.

Authors:  G L Bakris; M Williams; L Dworkin; W J Elliott; M Epstein; R Toto; K Tuttle; J Douglas; W Hsueh; J Sowers
Journal:  Am J Kidney Dis       Date:  2000-09       Impact factor: 8.860

8.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

9.  [Control of blood pressure in Spanish hypertensive population attended in primary health-care. PRESCAP 2006 Study].

Authors:  José L Llisterri Caro; Gustavo C Rodríguez Roca; Francisco J Alonso Moreno; José R Banegas Banegas; Diego González-Segura Alsina; Salvador Lou Arnal; Juan A Divisón Garrote; Tomás Sánchez Ruiz; José A Santos Rodríguez; Vivencio Barrios Alonso
Journal:  Med Clin (Barc)       Date:  2008-05-17       Impact factor: 1.725

Review 10.  Essential hypertension.

Authors:  Franz H Messerli; Bryan Williams; Eberhard Ritz
Journal:  Lancet       Date:  2007-08-18       Impact factor: 79.321

View more
  1 in total

1.  Reliability and Validity of the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q) in Persons with Arterial Hypertension.

Authors:  Jesús López-Torres López; Joseba Rabanales-Sotos; María Rosa López-Torres Hidalgo; Rosa María Milián García; Consuelo López Martínez; Gemma Blázquez Abellán
Journal:  Int J Environ Res Public Health       Date:  2021-03-19       Impact factor: 3.390

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.